Finance

Lists
YPH:FRA
Astellas Pharma Inc
€12.90
-2.27%
(-0.30) 1D
Sep 4, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for YPH...
Open
€12.80
High
€12.90
Low
€12.80
Mkt. cap
4.26T
Avg. vol.
108.00
Volume
0.00
52-wk high
€14.19
52-wk low
€8.56
No. of employees
14K
Open
€12.80
High
€12.90
Low
€12.80
Mkt. cap
4.26T
Avg. vol.
108.00
Volume
0.00
52-wk high
€14.19
52-wk low
€8.56
No. of employees
14K
Profile
Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. Astellas is a member of the Mitsubishi UFJ Financial Group keiretsu. Wikipedia
About Astellas Pharma Inc
CEONaoki Okamura
Employees14.1K
FoundedApr 1, 2005
HeadquartersChuo City, Tokyo, Japan
SectorPharmaceutical industry
Websiteastellas.com
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
524.32B
554.57B
537.92B
640.91B
Cost of goods sold
105.53B
104.03B
93.67B
122.70B
Cost of revenue
105.53B
104.03B
93.67B
122.70B
Research and development expenses
71.59B
85.77B
95.94B
81.73B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
206.84B
228.24B
234.70B
215.07B
Operating expense
325.88B
358.98B
336.48B
332.86B
Total operating expenses
431.41B
463.01B
430.14B
455.56B
Operating income
92.91B
91.55B
107.78B
185.35B
Other non operating income
-
1.50M
-241.00M
1.00M
EBT including unusual items
104.19B
90.99B
48.02B
186.51B
EBT excluding unusual items
92.38B
90.82B
113.57B
186.51B
Income tax expense
24.98B
19.02B
4.41B
44.76B
Effective tax rate
23.97%
20.90%
9.18%
24.00%
Other operating expenses
14.73B
9.72B
-29.93B
388.00M
Net income
79.21B
71.95B
43.52B
141.83B
Net profit margin
15.11%
12.97%
8.09%
22.13%
Earnings per share
-
-
-
-
Interest and investment income
2.15B
2.10B
1.29B
5.13B
Interest expense
-2.69B
-2.74B
-
-3.12B
Net interest expenses
-541.00M
-637.00M
1.29B
2.01B
Depreciation and amortization charges
-32.77B
-
35.76B
-
EBITDA
140.20B
141.30B
158.14B
235.24B
Gain or loss from assets sale
16.40B
-
31.51B
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps